<p>Experts at UCSF and Caltech are pushing the boundaries of creative problem solving to address important clinical problems with the hope that the talent pool at both institutions, combined with an entrepreneurial spirit, will advance health care innovation.</p>
Men and women had starkly different immune system responses to chronic post-traumatic stress disorder, with men showing no response and women showing a strong response, in two studies by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.
Researchers exploring human metabolism at UCSF have uncovered a handful of chemical compounds that regulate fat storage in worms, offering a new tool for understanding obesity and finding future treatments for diseases associated with obesity.
UCSF researchers have developed a new approach to decoding the vast information embedded in an organism’s genome, while shedding light on exactly how cells interpret their genetic material to create RNA messages and launch new processes in the cell.
UCSF scientists have received two grants from the California Institute for Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure.
A novel technique created at UCSF to deliver a growth factor directly to brain cells has shown promising results in treating Parkinson's symptoms and could enter human clinical trials as early as next year.
Taking an innovative path toward personalized medicine, scientists for the first time will be able to eliminate – at an early point in a clinical trial — experimental drugs that show poor efficacy, dramatically shortening the time it takes to get the right medication to the right patient with breast cancer.
A panel of experts appointed by Mayor Gavin Newsom recently presented an action plan as the approaching “age wave may bring a potential crisis in Alzheimer’s and dementia care” to San Francisco.
UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the <i>American Journal of Transplantation</i> that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.
Scientists have identified a gene family that plays a key role in one of the earliest stages of development in which an embryo distinguishes its left side from the right and determines how organs should be positioned within the body. The finding in mice likely will lead to a better understanding of how certain birth defects occur in humans.